Health and Healthcare
How Analysts Changed Views on BioMarin After Earnings
Published:
Last Updated:
BioMarin Pharmaceuticals Inc. (NASDAQ: BMRN) reported its fourth-quarter financial results after the markets closed Thursday. Investors really took to this stock and there was a favorable jump after the report. However, analysts took a slightly different perspective and cut their price targets.
The company said it had $0.40 in earnings per share (EPS) on $227.9 million in revenue, which compared to consensus estimates from Thomson Reuters of $0.99 in EPS on revenue of $224.38 million. The same period from last year had a net loss of $0.47 per share on $230.85 million in revenue.
In terms of guidance for 2016, the company expects to have a non-GAP net loss of in the range of $75 million to $100 million, as well as total revenues in the range of $1.05 billion to $1.10 million. The consensus estimates for the full year call for a net loss of $2.27 per share on $1.15 billion in revenue.
A few analysts weighed in on BioMarin after earnings:
Shares of BioMarin ended last week at $80.14, with a consensus analyst price target of $127.84 and a 52-week trading range of $62.12 to $151.75.
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.